Eli Lilly & Co. urged doctors to prescribe Zyprexa for elderly patients with dementia, an unapproved use for the antipsychotic, even though the drugmaker had evidence the medicine didn’t work for such patients, according to unsealed internal company documents.
In 1999, four years after Lilly sent study results to the U.S. Food and Drug Administration showing Zyprexa didn’t alleviate dementia symptoms in older patients, it began marketing the drug to those very people, according to documents unsealed in insurer suits against the company for overpayment.
Lilly Sold Drug for Dementia Knowing It Didn’t Help, Files Show
A smart drug that stops cancer cells “hiding” from treatment can shrink tumours by at least...
Claude Lemieux’s brain is being donated to the Boston University CTE Center to research the long-term...
99% of chemicals in our food right now were added without FDA approval. Many were added...
